Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

34 results
Display

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick K, Cataldi F, Watanabe M, Hibi T

Background/Aims: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials

Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara , Watanabe M

Background/Aims: Mucosal healing (MH) of distal lesions in ulcerative colitis (UC) has recently been confirmed with budesonide 2-mg foam (BF) treatment in 2 clinical trials; however, few studies have investigated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study

Hibi T, Motoya S, Ashida T, Sai S, Sameshima , Nakamura S, Maemoto A, Nii M, Sullivan B, Gasser Jr , Suzuki Y

BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T

BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

Nakagawa T, Kobayashi , Nishikawa , Yamada F, Asai S, Sameshima , Suzuki Y, Watanabe M, Hibi T

BACKGROUND/AIMS: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. METHODS: Patients were prospectively...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T

BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T

The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study

Ogata H, Yokoyama T, Mizushima , Hagino A, Hibi T

BACKGROUND/AIMS: This study compared the efficacy of multimatrix mesalazine 2.4 g/day and 4.8 g/day with controlled-release mesalazine 2.25 g/day. METHODS: In this multicenter, randomized, double-blind study, 251 patients with mildly to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T

BACKGROUND/AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries

Kobayashi , Hisamatsu , Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto , Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa , Sasaki M, Yokoyama K, Yoshimura , Watanabe K, Katafuchi , Watanabe M, Hibi T

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Highlights of the Third Expert Forum of Asia-Pacific Laparoscopic Hepatectomy; Endoscopic and Laparoscopic Surgeons of Asia (ELSA) Visionary Summit 2017

Park JI, Kim KH, Kim HJ, Cherqui D, Soubrane O, Kooby D, Palanivelu C, Chan A, You YK, Wu YM, Chen KH, Honda G, Chen XP, Tang CN, Kim JH, Koh YS, Yoon YI, Cheng KC, Duy Long T, Choi GH, Otsuka Y, Cheung TT, Hibi T, Kim DS, Wang HJ, Kaneko H, Yoon DS, Hatano E, Choi IS, Choi DW, Huang MT, Kim SG, Lee SG

The application of laparoscopy for liver surgery is rapidly increasing and the past few years have demonstrated a shift in paradigm with a trend towards more extended and complex resections....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis

Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu , Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T

Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease

Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi , Oshita M, Tanaka H, Ozeki K, Takahashi , Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T

BACKGROUND/AIMS: The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management

Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment

Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Inoue N, Kobayashi , Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson A, Thakkar RB, Hibi T

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study

Ogata H, Aoyama N, Mizushima , Hagino A, Hibi T

BACKGROUND/AIMS: This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine. METHODS: In this multicenter, randomized, double-blind study, 280 patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study

Ogata H, Ohori A, Nishino H, Mizushima , Hagino A, Hibi T

BACKGROUND/AIMS: This study compared the efficacy of once-daily administration of multimatrix mesalazine 2.4 g/day with multiple-dose mesalazine for the maintenance of remission. METHODS: In this multicenter, randomized, double-blind study, 203 patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr